Indianapolis, Indiana 46202

  • Thymic Carcinoma


To study the efficacy of Alimta as a single agent in thymic cancers

Study summary:

The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting efficacy of a single agent such as premetrexed a reasonable objective since these malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to antineoplastic agents.


Inclusion Criteria: - Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery. Original biopsy of tumor is sufficient for diagnoses unless otherwise clinically indicated. - Patients must have measurable disease with at least one bidimensional measurable lesion. Any scans or x-rays used to document measurable disease must be obtained with 6 weeks prior to registration. - Patients may have had prior chemotherapy for metastatic disease - Adequate organ function as defined by: bili </=1.5; calc. crt clr of >/=45; hematologic-granulocytes >/=1500 & plt >/=100K. - Patients who are receiving a stable dose of corticosteroids for myasthenia gravis are eligible. - ECOG performance status of 0 or 1 Exclusion Criteria: - Acute intercurrent infection or complications - pregnancy or lactating patients - Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents. - Presence of clinically relevant third-space fluid collections that cannot be controlled by a procedure



Primary Contact:

Principal Investigator
Patrick Loehrer, M.D.
Indiana University

Backup Contact:


Location Contact:

Indianapolis, Indiana 46202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.